在具有完整JAK2V617F抑制的骨髓增殖新生体中增强分子反应
Hamza Celik1, Grant A Challen2
1Incyte Research Institute, Wilmington, Delaware.
Cancer discovery
|May 1, 2024
概括
一个新的JAK2V617F小鼠模型显示,这些突变需要特定的细胞才能生存. 这表明有针对性的疗法可能可以治愈骨髓增殖性瘤,即使存在其他突变.
科学领域:
- 血液学 血液学 血液学
- 遗传学 是一个遗传学.
- 在瘤学瘤学.
背景情况:
- 该JAK2V617F突变是骨髓增殖性瘤 (MPNs) 的关键驱动因素.
- 了解JAK2V617F驱动的MPN的细胞需求对于开发有效的治疗方法至关重要.
研究的目的:
- 开发和描述一种具有可诱导和可逆JAK2V617F表达的新型遗传小鼠模型.
- 研究特定细胞群在由JAK2V617F驱动的MPN生存和传播中的作用.
主要方法:
- 创建一个小鼠模型,JAK2V617F表达通过可诱导和可逆系统控制在内源性位点.
- 在开发的小鼠模型中分析MPN发育,进展和细胞依赖.
主要成果:
- 这项研究表明,骨髓增殖性瘤发起细胞对于由JAK2V617F突变驱动的MPNs的生存至关重要.
- 在小鼠模型中,JAK2V617F的诱导和可逆表达允许详细研究其对造血干细胞和原生细胞的影响.
结论:
- 由JAK2V617F驱动的MPN绝对需要特定的启动细胞才能生存.
- 这些发现表明,针对这些必需细胞的高效抑制剂可以为MPN患者提供治疗潜力,即使是那些有合作突变的患者.
相关概念视频
Differentiation of Common Myeloid Progenitor Cells
3.2K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.2K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
The JAK-STAT Signaling Pathway
8.8K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.8K
PI3K/mTOR/AKT Signaling Pathway
3.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.5K
Multipotency of Hematopoietic Stem Cells
3.1K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.1K


